A call for clinical trial globalization in Alzheimer's disease and related dementia

for the Diversity and Disparity Professional Interest Area Increasing Sustained Diversity in Clinical Trials Working Group

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Background: The burden of Alzheimer's disease and related dementia (ADRD) is projected to disproportionally impact low-middle-income countries (LMICs). However, there is a systematic under-representation of LMICs in ADRD clinical trial platforms. Methods: We aimed to determine the global distribution of ADRD clinical trials and identify existing barriers for conducting clinical trials in LMICs. Primary data sources to identify trial distribution in LMICs included ClinicalTrials.gov and the International Trials Registry Platform. An additional systematic review and expert consensus interviews were conducted to identify barriers for conducting clinical trials in LMICs. Findings: Among 1237 disease-modifying therapies tested in ADRD clinical trials, only 11.6% have been or are conducted in emerging economies (upper-middle income [9.6%] and low-middle income [2.0%]). We identified several limitations for trial implementation including a lack of financial resources, low industry presence, regulatory obstacles, and operational barriers. Interpretation: Although LMICs bear the greatest burden of ADRD globally, substantial development of clinical trial platforms to address this inequity and health disparity is lacking.

Original languageEnglish
Pages (from-to)3210-3221
Number of pages12
JournalAlzheimer's and Dementia
Volume19
Issue number7
DOIs
StatePublished - Jul 2023

Fingerprint

Dive into the research topics of 'A call for clinical trial globalization in Alzheimer's disease and related dementia'. Together they form a unique fingerprint.

Cite this